Pharma Update

Success rate Roche with leading success rate by molecule... ...but higher Phase III failure rate recently Molecule success (PoL Preclinical - Approval) 2018-22 Industry Distribution Peer 13.8% 10.1% 9.9% Peer Roche Peer 8.7% Peer 8.7% Peer 8.0% Peer 6.2% Peer 6.0% Peer 5.4% Peer 4.7% Peer Peer 3.9% 2.9% Median Top quartile 11 Bottom quartile PTS Molecule Success Rate in Phase III* 2009-13 to 2018-22 100% 75% 50% 25% 0% 2009-13 76% 58% 2018-22 Time period 5-year rolling average (Roche) N=12 5-year rolling average (peers) N=106 *Values on the Molecule Success Rate trend in phase III graph represent outcomes in the 2018-22 horizon. Graphs start with 2009-13 data and then show 5-year average trend through 2018-22 horizon; PTS-probability of technical success; Source: KMR Benchmarking analysis 23 Roche

View entire presentation